15 November 2018 - - New Zealand-based software company Geneious Biologics, which offers a solution for companies engaged in screening of antibodies and antibody-like molecules, has been chosen by the VIB (a Life Sciences Research Institute in Belgium) to support therapeutic biologics discovery at its Discovery Sciences group, the company said.

VHHs are an extremely versatile class of molecules for research, diagnostics and therapeutics in human and animal health.

This powerful technology was discovered at the Vrije Universiteit Brussel and continues to be the subject of intensive research at VIB and at VIB Discovery Sciences, also available to academic and commercial partners through VIB's Core Facilities.

Geneious Biologics, is Biomatters' cloud-based enterprise software solution for analysis of antibodies and related constructs using DNA sequence data.

The software applies intuitive visualization tools and advanced analytics to help specialist biologic drug development companies accelerate identification of therapeutic candidates.

Biomatters said it offers software that transforms biological data into knowledge and actionable insights.

The company's Geneious software suite is used by over 3,000 companies, universities, and institutes in more than 100 countries. Geneious Biologics integrates with Biomatters' existing Geneious DNA analysis tools and leverages the company's deep expertise in delivering solutions that meet customers' real-life needs. 

VIB is a strategic research center in life sciences and biotech.

The results of VIB's top research are actively translated into added value for society. VIB unites the expertise of 75 research groups thematically organised into eight research centres.

VIB's technology transfer team proactively translates new biological findings into new economic activities, such as starting up new companies and partnerships with the biotech and pharmaceutical industry.

Since its foundation in 1996, VIB has created 20 start-up companies. VIB also engages actively in the public debate on biotechnology by developing and disseminating a range of science-based information about all aspects of biotechnology.

VIB has a close partnership with five Flemish universities Ghent University, KU Leuven, University of Antwerp, Vrije Universiteit Brussel and Hasselt University.